Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose pharmacokinetics and safety of fluticasone furoate + GW642444M via novel dry powder inhaler in healthy subjects and subjects with hepatic impairment
2010-020157-13Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fluticasone and vilanterol in hepatic impairment (4 arms), sponsored by GSK. Primary endpoints: Fluticasone furoate pharmacokinetics, GW642444 pharmacokinetics and 2 more. Started Jul 2010; status: terminated.
02
Drugs
fluticasonevilanterol
03
Conditions
hepatic impairment
Beyond the preview
Go deeper on 2010-020157-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020157-13.